08:07 EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE) Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SMMT: Summit Therapeutics Highlights Q4 Results and FDA Fast Track Summit Therapeutics reports Q4 EPS (7c), consensus (6c) Is SMMT a Buy, Before Earnings? Summit Therapeutics Grants Bonuses and Reports Strong Finances Summit Therapeutics Highlights Success at Healthcare Conference
